OXFORD, UK and MARLBOROUGH, MA, APR. 21, 2014 (GLOBE NEWSWIRE) – Oxford Immunotec Global PLC (NASDAQ: OXFD) today announced that it has received a Queen’s Award for Enterprise – the UK’s highest accolade in business success.
The Queen’s Awards are designed to recognise and encourage the achievements by businesses in the UK in the fields of Innovation, International Trade and Sustainable Development. The awards are made annually by Her Majesty The Queen and are only given for the highest levels of excellence demonstrated in each category.
Oxford Immunotec received a prestigious Queen’s Award for International Trade for Continuous Achievement, based on its substantial overseas revenue growth and commercial success over six years. From 2007 to 2012, Oxford Immunotec grew its overseas earnings by greater than 1300% through expansion into markets worldwide including the United States, Japan and China. The Company’s T-SPOT®.TB test for tuberculosis is now approved for sale in over 50 countries on five continents. The T-SPOT.TB test helps to diagnose tuberculosis infection before it has progressed to full-blown disease, allowing treatment of carriers to prevent further spread of TB infection and disease.
Commenting on the Company’s achievement, Dr Peter Wrighton-Smith, Oxford Immunotec’s Chief Executive Officer, said “We are delighted and honoured to have the achievements of the Company recognized by Her Majesty. We look forward to continuing to expand the countries we serve and in continuing our strong export-led growth”.
-Ends –
Notes to Editors:
About Oxford Immunotec Global PLC
Oxford Immunotec Global PLC is a global, commercial-stage diagnostics company committed to improving patient care by providing advanced, innovative tests in the field of immunology. The proprietary T-SPOT® technology platform measures the responses of specific immune cells, known as T cells, to inform the diagnosis, prognosis and monitoring of patients with immunologically controlled diseases. T cells are a central component of the human body’s immune system, and are implicated in the control and progression of many medical conditions, including certain types of infectious diseases, cancers and autoimmune diseases. The Company’s initial product developed using the T-SPOT technology platform is the T-SPOT.TB test, which is used to test for latent tuberculosis infection. The T-SPOT.TB test has been approved for sale in over 50 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China. The Company is headquartered near Oxford, UK and in Marlborough, MA and the Company’s shares are traded on The NASDAQ Global Market (NASDAQ:OXFD).
Oxford Immunotec was founded in 2002 to commercialise science originating from the University of Oxford. The Company now employs over 150 people in the UK, Continental Europe, US and Japan.
Additional information can be found at www.oxfordimmunotec.com.
T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd.
About The Queen’s Award Scheme
The Queen’s Awards Scheme, originally known as The Queen’s Award to Industry, was instituted by Royal Warrant in 1965 and the first awards were made in 1966. HM The Queen makes the Awards on the advice of the Prime Minister who is assisted by an Advisory Committee that includes representatives of Government, industry and commerce, and the trade unions. They are announced annually on 21 April, The Queen’s birthday, and are only given for the highest levels of excellence demonstrated in each category. Winners of The Queen’s Awards can expect an invitation to attend a special reception at Buckingham Palace.
For further information please visit www.queensawards.org.uk.
Forward-Looking Statements
This release contains forward-looking statements, including statements regarding future success of the company. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. Forward-looking statements are based on current expectations and assumptions and currently available data and are neither predictions nor guarantees of future events or performance. You should not place undue reliance on forward-looking statements, which speak only as of the date of this presentation. We do not undertake to update or revise any forward-looking statements after they are made, whether as a result of new information, future events, or otherwise, except as required by applicable law.
CONTACTS:
For Media Inquiries:
Caroline Crawley
Oxford Immunotec
Tel: +44 1235 442796
ccrawley@oxfordimmunotec.com
For Investor Inquiries:
Rick Altieri
Chief Financial Officer,
Oxford Immunotec
Tel: +1 (508) 481-4648
raltieri@oxfordimmunotec.com
Mark Klausner
Westwicke Partners
Tel: +1 (443) 213-0500
oxfordimmunotec@westwicke.com
SOURCE: Oxford Immunotec
